The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...

Novo Nordisk and Hims & Hers have come to an agreement that will see the telehealth company sell Novo’s branded glucagon-like ...

Hims & Hers Health partners with Novo Nordisk to sell weight loss medications, ending patent lawsuit. Shares surge 40% as companies reach agreement on Wegovy and Ozempic distribution.

The two struck a deal Monday for Hims to offer official versions of Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy.

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.

Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped ...

Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug Wegovy.

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker ...

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

Anti-vaccine activists rallied in Washington on Monday at a conference on vaccine injury to push for policies that would strip liability protections from vaccine makers.

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...